Anonymous
Guest
Anonymous
Guest
AstraZeneca shareholders upset at rejection of Pfizer offer • 7:08 AM
Leading AstraZeneca (AZN) shareholders aren't happy about the company's rebuffing of Pfizer's latest £69B ($117B) offer.
Jupiter Fund Management, a top-30 shareholder in the U.K. pharmaceuticals provider, is "disappointed" that the rejection was so categorical. "They should have at least engaged in a constructive conversation...to assess the opportunities that a combined entity could bring," Jupiter says.
A fund manager at a top 10 investor says: "We do not think the Astra management have done a good job on behalf of shareholders."
AstraZeneca's shares are -12% premarket.
By Seeking Alpha
Leading AstraZeneca (AZN) shareholders aren't happy about the company's rebuffing of Pfizer's latest £69B ($117B) offer.
Jupiter Fund Management, a top-30 shareholder in the U.K. pharmaceuticals provider, is "disappointed" that the rejection was so categorical. "They should have at least engaged in a constructive conversation...to assess the opportunities that a combined entity could bring," Jupiter says.
A fund manager at a top 10 investor says: "We do not think the Astra management have done a good job on behalf of shareholders."
AstraZeneca's shares are -12% premarket.
By Seeking Alpha